Antituberculosis drug-induced hepatotoxicity is uncommon in Tanzanian hospitalized pulmonary TB patients

Tropical Medicine and International Health

Volumn 15, Issue 2, 2010, Pages 268-272

  Tostmann, Alma ^a   Van Den Boogaard, Jossy ^a   Semvua, Hadija ^b   Kisonga, Riziki ^c   Kibiki, Gibson S ^b   Aarnoutse, Rob E ^a   Boeree, Martin J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b KILIMANJARO CHRISTIAN MEDICAL CENTRE   (Tanzania)

^c Kibong'Oto National Tuberculosis Hospital   (Tanzania)

Author keywords

Adverse reactions; Africa; Antitubercular treatment; Liver toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

COHORT ANALYSIS; DISEASE CONTROL; DRUG PRESCRIBING; HEPATITIS; HUMAN IMMUNODEFICIENCY VIRUS; RISK FACTOR; TOXICITY; TUBERCULOSIS;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL TRIAL; CONJUNCTIVA DISCOLORATION; CONJUNCTIVA DISEASE; FEMALE; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; INTENSIVE CARE; JAUNDICE; LIVER FUNCTION; LIVER TOXICITY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; PATIENT MONITORING; SIDE EFFECT; TANZANIA;

ADULT; ANTITUBERCULAR AGENTS; DRUG-INDUCED LIVER INJURY; FEMALE; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; TANZANIA; TUBERCULOSIS, PULMONARY;

TANZANIA;

EID: 74349105945     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2009.02449.x     Document Type: Article

References (26)

1. Baghaei P, Tabarsi P, Chitsaz E et al. (2009) Incidence, Clinical and Epidemiological Risk Factors, and Outcome of Drug-Induced Hepatitis Due to Antituberculous Agents in New Tuberculosis Cases. American Journal of Therapeutics [Epub ahead of print].
2. Bertino J Fish D (2000) The safety profile of the fluoroquinolones. Clinical Therapeutics 22, 798 817.
3. Burman WJ, Gallicano K Peloquin C (2001) Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clinical Pharmacokinetics 40, 327 341.
4. Chelule PK, Pegoraro RJ, Gqaleni N Dutton MF (2006) The frequency of cytochrome P450 2E1 polymorphisms in Black South Africans. Disease Markers 22, 351 354.
5. Corbett EL, Watt CJ, Walker N et al. (2003) The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Archives of Internal Medicine 163, 1009 1021.
6. Dandara C, Sayi J, Masimirembwa CM et al. (2002) Genetic polymorphism of cytochrome P450 1A1 (Cyp1A1) and glutathione transferases (M1, T1 and P1) among Africans. Clinical Medicine and Laboratory Medicine 40, 952 957.
7. Dean GL, Edwards SG, Ives NJ et al. (2002) Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 16, 75 83.
8. Ho CC, Chen YC, Hu FC et al. (2009) Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens. Clinical Infectious Diseases 48, 1526 1533.
9. Hoffmann CJ, Charalambous S, Thio CL et al. (2007) Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS 21, 1301 1308.
10. Johnson JL, Okwera A, Nsubuga P et al. (2000) Efficacy of an unsupervised 8-month rifampicin-containing regimen for the treatment of pulmonary tuberculosis in HIV-infected adults. Uganda-Case Western Reserve University Research Collaboration. International Journal of Tuberculosis and Lung Disease 4, 1032 1040.
11. Kaona FA, Tuba M, Siziya S Sikaona L (2004) An assessment of factors contributing to treatment adherence and knowledge of TB transmission among patients on TB treatment. BMC Public Health 4, 68.
12. Kovacs JA, Hiemenz JW, Macher AM et al. (1984) Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Annals of Internal Medicine 100, 663 671.
13. Kwara A, Flanigan TP Carter EJ (2005) Highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status. International Journal of Tuberculosis and Lung Disease 9, 248 257.
14. Marks DJ, Dheda K, Dawson R, Ainslie G Miller RF (2009) Adverse events to antituberculosis therapy: influence of HIV and antiretroviral drugs. International Journal of STD and AIDS 20, 339 345.
15. Matimba A, Del-Favero J, Van BC Masimirembwa C (2009) Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects. Human Genomics 3, 169 190.
16. Nunez M (2005) Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. Journal of Hepatology 44, S132 S139.
17. Perriens JH, St Louis ME, Mukadi YB et al. (1995) Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. New England Journal of Medicine 332, 779 784.
18. Sabbagh A, Langaney A, Darlu P et al. (2008) Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history. BMC Genetics 9, 21.
19. Sanne I, Mommeja-Marin H, Hinkle J et al. (2005) Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. Journal of Infectious Diseases 191, 825 829.
20. Saukkonen JJ, Cohn DL, Jasmer RM et al. (2006) An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy. American Journal of Respiratory and Critical Care Medicine 174, 935 952.
21. Sun F, Chen Y, Xiang Y Zhan S (2008) Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis. International Journal of Tuberculosis and Lung Disease 12, 994 1002.
22. Tostmann A, Boeree MJ, Harries AD et al. (2007) Short communication: antituberculosis drug-induced hepatotoxicity is unexpectedly low in HIV-infected pulmonary tuberculosis patients in Malawi. Tropical Medicine and International Health 12, 852 855.
23. Tostmann A, Boeree MJ, Aarnoutse RE et al. (2008) Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. Journal of Gastroenterology and Hepatology 23, 192 202.
24. Wares DF, Singh S, Acharya AK Dangi R (2003) Non-adherence to tuberculosis treatment in the eastern Tarai of Nepal. International Journal of Tuberculosis and Lung Disease 7, 327 335.
25. World Health Organization (2009) Global Tuberculosis Control 2009: Surveillance, Planning, Financing: WHO Report 2009. WHO, Geneva. http://www.who.int/tb/publications/global-report/2009/pdf/full-report.pdf
26. World Health Organization/IUATLD Global project on anti-tuberculous drug Resistance Surveillance (2008) Anti-Tuberculosis Drug Resistance in the World. Fourth Global Report. WHO, Geneva. http://whqlibdoc.who.int/hq/2008/WHO-HTM-TB- 2008.394-eng.pdf